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Self-reactive lymphocytes that escape elimina-
tion during development can cause autoimmune 
diseases later in life. Structural characterization 
of a substantial number of self-reactive TCRs is 
necessary to define at a repertoire level how 
such TCRs can productively engage self-antigen 
despite the need to escape deletion. Five struc-
tures have thus far been determined, involv-
ing two human TCRs from multiple sclerosis 
(MS) patients (Hahn et al., 2005; Li et al., 2005) 
and three murine TCRs from the experimental 
encephalomyelitis (EAE) model of MS (Maynard 
et al., 2005; Feng et al., 2007). The two human 
TCRs  (Ob.1A12  and  3A6)  showed  a  shift   
toward the peptide N terminus that reduced 
TCR interaction with HLA-DR (abbreviated 
as DR)–bound peptides from myelin basic pro-
tein (MBP; Hahn et al., 2005; Li et al., 2005; 
Wucherpfennig  et  al.,  2009). Although  three 
murine TCRs  bound  with  normal  topology, 
they also showed a suboptimal interaction with 
the self-peptide because only part of the groove 
was filled by the N-terminal MBP Ac1-11 epi-
tope (He et al., 2002). The MBP Ac1-11 pep-
tide bound with very low affinity to the relevant 
MHC  molecule  (I-Au;  Fairchild  et  al.,  1993; 
Harrington et al., 1998), and in MBP-deficient 
mice the T cell response to MBP was focused 
on C-terminal peptides that bound with substan-
tially higher affinity to I-Au (Harrington et al., 
1998).  Negative  selection  of  these T  cells  in 
wild-type mice thus permitted the Ac1-11 pep-
tide to become immunodominant even though 
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Self-reactive T cells that escape elimination in the thymus can cause autoimmune pathol-
ogy, and it is therefore important to understand the structural mechanisms of self-antigen 
recognition. We report the crystal structure of a T cell receptor (TCR) from a patient with 
relapsing-remitting multiple sclerosis that engages its self-peptide–major histocompatibil-
ity complex (pMHC) ligand in an unusual manner. The TCR is bound in a highly tilted orien-
tation that prevents interaction of the TCR- chain with the MHC class II  chain helix.  
In this structure, only a single germline-encoded TCR loop engages the MHC protein, whereas 
in most other TCR-pMHC structures all four germline-encoded TCR loops bind to the MHC 
helices. The tilted binding mode also prevents peptide contacts by the short complementarity-
determining region (CDR) 3 loop, and interactions that contribute to peptide side chain 
specificity are focused on the CDR3 loop. This structure is the first example in which only 
a single germline-encoded TCR loop contacts the MHC helices. Furthermore, the reduced 
interaction surface with the peptide may facilitate TCR cross-reactivity. The structural 
alterations in the trimolecular complex are distinct from previously characterized self-
reactive TCRs, indicating that there are multiple unusual ways for self-reactive TCRs to 
bind their pMHC ligand.
© 2011 Sethi et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(abbreviated as DQ1). The T cell response to MBP in this   
patient was dominated by three in vivo expanded T cell clones 
specific for the MBP85-99 peptide that persisted over time. Two 
of these clones were DR restricted (DRA, DRB1*1602)   
and  one  was  DQ1  restricted  (DQAI*0102,  DQBI*0502; 
Wucherpfennig et al., 1994a,b). A total of three clones with 
the Hy.1B11 TCR sequence (TRAV13-1*02, TRAJ48*01, 
and TRBV7-3*01, TRBD2*01, TRBJ2-3*01) were isolated 
from independent cultures, two from the initial time point 
and a third 13 mo later (Wucherpfennig et al., 1994b). Fur-
thermore, this T cell clone was activated by four microbial 
peptides (from herpes simplex virus, adenovirus, human   
papillomavirus, and pseudomonas) that had limited sequence 
similarity to the MBP85-99 peptide (Wucherpfennig and 
Strominger, 1995). The structure showed that only one of the 
two CDR3 loops contacted the bound peptide, explaining 
why specificity was limited to few peptide residues. This self-
reactive TCR thus followed some of the rules established for 
antimicrobial TCRs (such as binding of the TCR- chain to 
the MHC 1 helix) while clearly violating other rules (no 
MHC helix contacts by TCR- germline-encoded loops and 
peptide contacts by only one CDR3 loop).  The structure thereby 
reveals a novel way of self-pMHC recognition by a TCR from 
a patient with a chronic inflammatory disease.
RESULTS
Unusual features of Hy.1B11 TCR binding  
to the self-pMHC complex
The complex of Hy.1B11 TCR and DQ1-MBP85-99 peptide 
crystallized in the space group P212121, and one of the crystals 
diffracted to a resolution of 2.55 Å. The structure was deter-
mined by molecular replacement with one molecule in the 
asymmetric unit and refined to Rwork/Rfree values of 23.2 and 
25.8%, respectively. Crystal data and refinement statistics for 
the structure are shown in Table S1. Excellent electron density 
was observed at the interface for the CDR loops of the TCR, 
the peptide, and the DQ1 helices (Fig. S1). The structure 
showed a strong tilt in TCR binding toward the DQ1 1 helix, 
which prevented interaction of the TCR V chain with the 
DQ1 1 helix (Fig. 1, a, c, and e). The tilt was 14.5° com-
pared with the influenza hemagglutinin (HA306-318)-specific 
HA1.7 TCR (Hennecke et al., 2000; Fig. 1, b, d, and f), mea-
sured using a vector through the centers of mass of the  V and 
V domains. In addition, a small crossing angle (40°) of the 
TCR over the pMHC surface was observed which appar-
ently prevented MHC engagement by the CDR1 loop. This   
crossing angle was smaller than for any other studied MHC 
class II restricted TCR (Fig. S2), but a similar crossing angle 
had been observed for the MHC class I restricted 2C TCR 
(Garcia et al., 1998; Rudolph et al., 2006). As a result of the 
tilt and the small crossing angle, the center of mass of the V 
domain was shifted toward the peptide by 6 Å compared 
with HA1.7, and the center of mass of the V domain was 
also shifted by 6.5 Å (Fig. S2). The tilted position resulted in 
limited Hy.1B11 TCR interaction with the DQ1 1 helix 
(Table  I)  and  also  substantially  reduced TCR  interactions 
it only partially occupied the binding groove. These results 
suggest that the observed structural defects in these trimolec-
ular recognition units are caused by selection events that 
eliminated self-reactive T cells with optimal TCR binding 
properties. T cells that expressed the three EAE TCRs were 
pathogenic (Goverman et al., 1993; Lafaille et al., 1994; 
Pearson et al., 1997), and transgenic mice that expressed the 
human Ob.1A12 TCR and the relevant human MHC molecule 
developed  spontaneous  CNS  inflammation  and  demyelin-
ation (Madsen et al., 1999; Ellmerich et al., 2005). These TCRs 
thus have altered binding properties that apparently enabled 
escape from negative selection but still allowed them to bind to 
their target peptide–MHC (pMHC) complex with sufficient 
strength to cause disease. The vast majority of antimicrobial 
TCRs are positioned over the center of the pMHC surface. 
An N-terminal shift has so far been observed in one case, ap-
parently also as a result of self-tolerance mechanisms (Gras et al., 
2009). This TCR (CF34) was specific for an HLA-B8–bound 
EBV peptide and originated from a person who was HLA-B8 
and HLA-B44 heterozygous. The N-terminal shift by this 
TCR appeared to prevent self-reactivity to HLA-B44. In con-
trast, the LC13 TCR was alloreactive for HLA-B44 because   
it was isolated from a person who expressed HLA-B8 but   
not HLA-B44. This TCR bound over the C-terminal part of 
the HLA-B8–bound EBV peptide (Gras et al., 2009).
However, the structural database is still too small to ade-
quately describe the recognition properties of self-reactive   
T cells at a repertoire level, and a substantially larger number 
of complexes needs to be crystallized to determine to what 
extent self-reactive TCRs deviate from the rules followed by 
most antimicrobial TCRs. In particular, the range of possible 
binding solutions by human autoimmune T cells remains 
largely unexplored. A large number of crystal structures, as 
well as functional studies, have shown that antimicrobial 
TCRs use a diagonal binding mode that positions the four 
germline-encoded TCR loops (complementarity-determining 
region [CDR] 1 and CDR2 of TCR- and -) over the 
MHC helices (Sun et al., 1995; Garboczi et al., 1996; Garcia 
et al., 1996; Garcia and Adams, 2005; Rudolph et al., 2006; 
Marrack et al., 2008). In most structures, the CDR3 loops 
also contribute to MHC binding. This binding mode allows 
the two hypervariable CDR3 loops to make extensive con-
tacts with the bound peptide. In addition, peptide contacts are 
frequently made by the CDR1 and  loops to N-terminal 
and C-terminal peptide residues, respectively. A substantial 
body of recent work has suggested that the observed place-
ment of the germline-encoded CDR1 and CDR2 loops on 
the MHC helices is the product of coevolution of MHC and 
TCR genes (Turner et al., 2006; Feng et al., 2007; Dai et al., 
2008; Garcia et al., 2009).
Previous studies on human autoimmune TCRs focused 
on two DR-restricted T cell clones specific for MBP from 
MS patients. We now report the crystal structure of a human 
TCR (Hy.1B11) from a relapsing-remitting MS patient that 
recognizes the same MBP peptide (residues 85–99) as Ob.1A12 
TCR but presented by a different MHC molecule, HLA-DQ1 JEM VOL. 208, January 17, 2011 
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by the CDR3 loop because the CDR1 and CDR2 loops 
did not bind to DQ1.
Only a single germline-encoded Hy.1B11 TCR loop binds  
to HLA-DQ1
Four germline-encoded TCR loops, CDR1 and CDR2 of 
both TCR chains (Fig. 2 b, yellow), and both CDR3 loops 
(Fig. 2 b, red) typically contact the MHC helices, as illustrated 
for the human HA1.7 TCR (Hennecke et al., 2000). In stark 
contrast, only a single germline-encoded loop of Hy.1B11 
TCR (CDR2) bound to DQ1 (Fig. 2 a). There were no 
contacts between the TCR  V domain and the DQ1 1 helix, 
and only a single residue on the DQ1 1 helix (E66) was 
contacted by Hy.1B11 TCR (through CDR3; Fig. 2 e and 
Table I). Hy.1B11 TCR thus formed extensive interactions 
with the DQ1 1 helix but only limited contacts with the 
DQ1 1 helix (Fig. 2, c and e), whereas HA1.7 TCR had ex-
tensive interactions with both MHC helices (Fig. 2, d and f). 
The absence of MHC binding by three of the germline-
encoded TCR loops was partially compensated by both CDR3 
loops, in particular CDR3, which made a substantial num-
ber of contacts with the DQ1 1 helix (Table I; Fig. 2, c and e). 
Two distinctive features of Hy.1B11 TCR binding were re-
sponsible for this highly unusual interaction with the MHC 
molecule:  the  tilt  that  prevented  DQ1  binding  by  the 
germline-encoded TCR- loops and a small crossing angle.   
with the peptide (Fig. 1 e), as discussed below in greater detail. 
In contrast, HA1.7 TCR made a large number of contacts 
with both MHC helices and the HA peptide (Fig. 1 f). The 
total buried surface area of the complex was 1645 Å2, of 
which  approximately  half  was  contributed  by TCR  and 
pMHC, respectively. Overall, the peptide contributed 36% of 
the pMHC buried surface area, with the remainder contrib-
uted by the MHC protein. The TCR- chain contributed 
almost half (44%) of the total buried surface area, but 85% of 
the surface area buried by the TCR- chain was contributed 
Figure 1.  The highly tilted Hy.1B11 TCR binding mode prevents 
MHC contact by the germline-encoded TCR- chain loops. The  
self-reactive Hy.1B11 TCR (a, c, and e) is compared with the influenza  
HA-specific HA1.7 TCR (b, d, and f). The TCR- and - variable domains 
are colored in yellow and red, respectively, the MHC molecules in blue, and 
peptides in green. TCR and MHC constant domains have been omitted for 
clarity. The trimolecular complexes formed by Hy.1B11 and HA1.7 TCRs are 
viewed from the peptide C terminus (a and b) and rotated by 90° (c and d). 
The CDR1 and CDR2 loops of Hy.1B11 TCR are labeled (c). CDR1 (1) 
is colored orange, CDR2 (2) cyan, and CDR3 purple. Hy.1B11 (e) and 
HA1.7 (f) TCR residues that contact the respective pMHC complex are 
colored yellow for TCR- and red for TCR-.
Table I.  Contacts of Hy.1B11 TCR with HLA-DQ1
CDR TCR residue DQ1 residue Number  
of contacts
Contacts of TCR with HLA-DQ1
CDR3 G96 Q57 2
CDR3 G96 G58* 2
CDR3 N97 D55 2
CDR3 N97 Q57 3
CDR3 E98 R61** 11
CDR2 Y46 R61 1
CDR2 Q48 R61 1
CDR2 Q48 A64 1
CDR2 Q48 V65 4
CDR2 G49 H68 3
CDR2 T50 H68* 4
CDR2 A52 A64 1
CDR2 A53 A64 3
CDR2 A53 R61 1
CDR2 A53 Q57* 2
CDR2 A53 L60 1
CDR2 D54 Q57 4
CDR3 L95 R61 1
Contacts of TCR with HLA-DQ1
CDR3 A94 E66 3
CDR3 L95 E66 2
*, Putative hydrogen bond; **, two putative hydrogen bonds.94 Altered self-pMHC engagement by an autoreactive TCR | Sethi et al.
1 chain helix (Fig. 3 d, showing B3K506 TCR as an exam-
ple; Feng et al., 2007; Dai et al., 2008; Garcia et al., 2009). 
Furthermore, mutation of this loop in TCR- single chain 
transgenic mice interfered with T cell development (Scott-
Browne et al., 2009). Comparison of Hy.1B11 TCR, two other 
human TCRs (HA1.7 and 3A6), and the mouse B3K506 
TCR (as well as four other investigated TCRs; not depicted) 
showed a similar overall positioning of this CDR2 loop on 
the MHC class II 1 helix (Fig. 3, a–d; Marrack et al., 2008). 
Among all four TCRs, CDR2 residues 48 and 54 contacted 
the same positions on the MHC class II 1 helix (positions 61 
and 57, respectively; Fig. 3 e), even though many of the inter-
acting MHC and TCR side chains were chemically different. 
In addition, CDR2 residue 46 of Hy.1B11 and B3K506 
TCRs interacted with residue 61 on the MHC 1 helix, 
whereas CDR2 residue 53 of both Hy.1B11 and 3A6 TCR 
bound to positions 57 and 61 on the MHC. Although the 
The tilt prevented engagement of CDR1 and CDR2, and 
the small crossing angle shifted CDR3 toward the DQ1   
1 helix. This TCR thus represents the first example in which 
the MHC molecule is recognized by only one of the four 
germline-encoded TCR loops.
Positioning of the Hy.1B11 CDR2 loop on DQ1
Despite these highly unusual features, the Hy.1B11 TCR was 
positioned diagonally on the pMHC complex similar to other 
TCRs. The CDR2 loop contributed >70% of the surface 
area buried by the TCR- chain, and we therefore examined 
its interaction with the DQ1 1 helix in detail. Crystallo-
graphic studies of TCRs that used V8.2 identified a com-
mon binding mode of the CDR2 loop on the MHC class II 
Figure 2.  Only a single germline-encoded loop of Hy.1B11 TCR 
interacts with MHC. The CDR loops that contact the MHC helices are 
shown for two human MHC class II restricted TCRs (Hy.1B11 and HA1.7;  
a and b, respectively). The germline-encoded CDR1 and CDR2 loops which 
contact MHC are colored yellow, hypervariable CDR3 loops red, and CDR1/
CDR2 loops contacting only peptide gray. Only loops making contact with 
MHC or peptide are shown. MHC class II molecules are rendered as a sur-
face colored in blue. Peptides are colored teal. TCR- CDR loops are la-
beled as 1, 2, and 3, and TCR- loops as 1, 2, and 3. Footprint of 
TCR Hy.1B11 (c) and HA1.7 (d) on their pMHC ligand is shown. MHC is 
rendered as a surface. TCR contacts with the MHC 1 helix are colored 
yellow, and MHC 1 helix orange. Peptide surfaces are colored light green. 
Peptide residues contacted by TCR are colored dark green. Contacts with 
the MHC helices made by Hy.1B11 (e) and HA1.7 TCR (f) are colored yellow 
for the MHC class II 1 helix and orange for the MHC class II 1 helix.
Figure 3.  The overall placement of the Hy.1B11 CDR2 loop on 
the MHC class II 1 helix is similar to other structures. The place-
ment of the CDR2 loop of Hy.1B11 TCR (a) on the MHC class II 1 helix 
is compared with two other human TCRs (HA1.7 and 3A6; b and c, respec-
tively) and a murine TCR (B3K506, d). MHC class II residues on the  
1 helix contacted by multiple TCRs are highlighted as yellow spheres. 
The CDR2 loop is colored red and only side chains making contact to the 
MHC molecule are shown. CDR2 residues, as well as interacting MHC  
1 helix residues, are listed (e). Contacts made by multiple TCRs are high-
lighted in yellow.JEM VOL. 208, January 17, 2011 
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peptide positions in the P2 to P5 segment was further investi-
gated using a panel of single amino acid analogues for each 
position that represented all naturally occurring amino acids 
except cysteine (Fig. 5, c–f). Consistent with the structural data, 
the highest degree of specificity was observed for P3 Phe 
and P5 Lys, which showed a preference for hydrophobic and 
basic amino acids, respectively (Fig. 5, d and f). In contrast, 
more than half of the analogues of P2 His showed stimulatory 
activity (Fig. 5 c). An analogue with a phenylalanine-to- 
glycine substitution at P3 was active, possibly as a result of 
new contacts enabled by the well-established flexibility of 
CDR3 loops (Fig. 5 d; Garcia et al., 1998). P4 Phe represented 
an anchor residue for DQ1 binding that was deeply buried in 
the DQ1 binding groove (Fig. S3). This pocket had a prefer-
ence for large hydrophobic residues, but smaller hydrophobic 
residues and histidine were also tolerated (Fig. 5 e). In the 
structure, a few contacts were also made to peptide positions 
P-3 Asn (by CDR1) and P8 Val (by CDR1 and CDR2). 
These contacts were mediated through the peptide back-
bone. Consistent with this fact, substitution of these peptide 
residues by alanine did not reduce activity. These data thus 
support the functional relevance of the structural data and 
demonstrate that the majority of functionally important pep-
tide contacts are made by a single TCR loop, CDR3.
Intermediate binding affinity of Hy.1B11 TCR
Surface plasmon resonance measurements were performed to 
compare the binding affinity of the MBP85-99-specific Hy.1B11 
and Ob.1A12 TCRs for their ligands (DQ1-MBP85-99 and 
DR2-MBP85-99,  respectively).  Monobiotinylated  pMHC 
complexes were captured on a streptavidin sensor chip and 
soluble Hy.1B11 or Ob.1A12 TCR was injected over these 
surfaces. Hy.1B11 TCR bound to DQ1-MBP85-99 with a Kd 
of 14.3 µM based on equilibrium binding data (Fig. 6 b and 
Fig. 7 b). In contrast, the affinity of Ob.1A12 TCR for DR2/
MBP85-99 was lower, at 100 µM (our measurements; Cole   
et. al., 2007). Hy.1B11 TCR binding was specific because a 
control TCR (Ob.1A12) showed no binding to DQ1-MBP85-99 
overall positioning of the 2 loops on the MHC class II 1 helix 
was similar, the molecular details of the interactions were dis-
tinct as a result of differences in docking angles, MHC polymor-
phisms, and the actual sequences of the TCR CDR2 loops.
Only one of the CDR3 loops interacts with the MBP peptide
In most previously examined complexes of TCR and pMHC, 
both CDR3 loops contacted the bound peptide (as exempli-
fied by HA1.7 TCR; Fig. 4 b). CDR3 apparently could not 
contact the DQ1-bound peptide because of its short length 
and the unusual tilt of Hy.1B11 TCR. The Hy.1B11 CDR3 
loop was 10 amino acids in length compared with 9–16 
amino acids in other TCR structures (Table S2). The majority 
of peptide contacts were instead made by the CDR3 loop, 
in particular F95 (TRAJ48), which was inserted deeply be-
tween the P2 His and P3 Phe side chains of the peptide (Fig. 4 a 
and Table II). Furthermore, the main chain carbonyl of F95 
formed a hydrogen bond with P5 Lys of the peptide. Only 
one other residue of this CDR3 loop, E98, contributed to 
peptide recognition through two contacts with P5 Lys. Func-
tional experiments using a set of single amino acid analogue 
peptides confirmed that peptide specificity of the Hy.1B11   
T cell clone was limited to the P2 to P5 peptide segment to 
which the CDR3 loop bound. All alanine analogues within 
this segment showed a substantial reduction in  T cell proliferation 
at a low peptide concentration (100 nM; Fig. 5 a). However, only 
the alanine substitution of P5 Lys resulted in a complete loss of 
activity at a higher peptide concentration (1 µM; Fig. 5 b), sug-
gesting  an  energetically  important  contribution  of  bonds 
made to the P5 Lys sidechain. TCR specificity for the four 
Figure 4.  Only one of the Hy.1B11 CDR3 loops interacts with the 
peptide. The interaction of the CDR3 loops with peptide is compared for 
TCRs Hy.1B11 (a) and HA1.7 (b). CDR3 (red) and CDR3 (blue) are repre-
sented as loops, and side chains interacting with the peptide are shown. 
Hydrogen bonds are indicated as red dashes.
Table II.  Contacts of Hy.1B11 TCR with the MBP85-99 peptide
CDR TCR residue Residue  
of peptide
Number  
of contacts
Contacts to peptide by TCR- chain
CDR1 S28# P-3 Asn 1
CDR3 F95 P2 His 15
CDR3 F95 P3 Phe 7
CDR3 F95* P5 Lys 3
CDR3 E98 P5 Lys 2
Contacts to peptide by TCR- chain
CDR1 Thr28 P8 Val 2
CDR2 Gln48 P8 Val 2
CDR2 Gly49 P8 Val 3
Putative hydrogen bond to peptide sidechain (*) or to peptide backbone (#).96 Altered self-pMHC engagement by an autoreactive TCR | Sethi et al.
the site of negative selection, whereas HLA-DR protein could 
be readily detected (Ishikura et al., 1987). It is also well known 
that HLA-DQ molecules are expressed at substantially lower 
levels (10-fold) than HLA-DR molecules on peripheral   
antigen-presenting cells (Roucard et al., 1996). Direct com-
parison of Hy.1B11 and Ob.1A12 T cell clones showed that 
Hy.1B11 T cells required higher concentrations of MBP85-99 
peptide for stimulation, despite the higher affinity of Hy.1B11 
TCR for its pMHC ligand (Wucherpfennig et al., 1994a). 
The higher affinity of Hy.1B11 compared with Ob.1A12 TCR 
may therefore compensate for the substantially lower level   
of HLA-DQ than HLA-DR expression.
Mutagenesis of MHC and peptide contacts
Given this unusual binding topology, alanine scanning muta-
genesis was performed to validate the structure and to define 
(Fig. S4) and Hy.1B11 TCR did not bind to either DQ1-
CLIP or DR2/MBP85-99 control complexes (not depicted). 
Consistent with these affinity measurements, Hy.1B11 TCR 
had a higher shape complementarity (0.63) than Ob.1A12 
TCR (0.51) for its pMHC ligand, whereas the solvent in-
accessible area was in a similar range for both TCRs (1,645 and 
1,688 Å2 for the complexes formed by Hy.1B11 and Ob.1A12 
TCRs, respectively). Greater shape complementarity can re-
sult in higher affinity (Garcia et al., 1998; Reinherz et al., 
1999), but it remains unknown whether this aspect explains 
the moderately higher affinity of Hy.1B11 compared with 
Ob.1A12 TCR.
The differences in binding affinities between Hy.1B11 
and Ob.1A12 may be related to differences in HLA-DQ and 
HLA-DR expression levels and patterns. Histological studies 
showed very low expression of HLA-DQ in the thymic medulla, 
Figure 5.  Specificity of TCR recognition is limited to a short segment of the MBP peptide. T cell proliferation induced by a panel of single amino 
acid alanine analogues of the MBP85-101 peptide (indicated as P-4 to P11 for each position in the MBP85-99 region) as well as the native MBP85-101 peptide 
at concentrations of 100 nM (a) or 1 µM (b). Four peptide positions with reduced responses to the alanine analogues (P2 His, P3 Phe, P4 Phe, and P5 Lys) 
were further examined with a set of 18 single amino acid analogue peptides representing all naturally occurring amino acids (except cysteine) in a T cell 
proliferation assay at a concentration of 100 nM (c–f). T cell proliferation was measured by [3H]-thymidine incorporation using EBV-transformed B cells 
expressing DQ1 as antigen-presenting cells. Experiments were independently performed twice with similar results. Additional experiments performed with 
smaller sets of peptides also confirmed the conclusions. The data represent the mean and standard deviation of triplicate measurements.
Figure 6.  Hy.1B11 TCR binds with an 
intermediate affinity to the DQ1–MBP 
peptide complex. (a) Different concentrations 
of monomeric Hy.1B11 TCRs (0.75, 1.5, 3, 6, 12, 
24, and 96 µM) were injected over a flow cell 
with immobilized DQ1-CLIP (700 RU), followed 
by a flow cell with immobilized DQ1-MBP85-99 
(700 RU) at a flow rate of 15 µl/min. TCR was 
injected for 2 min at 25°C. The signal from the 
DQ1-CLIP reference flow cell was subtracted 
from the DQ1-MBP85-99 flow cell and data 
were fitted to a 1:1 (Langmuir) binding model 
using BIAevaluation software. (b) For equilib-
rium binding analysis nine serial dilutions were injected using the same setup as in (a), and the equilibrium-binding constant Kd was calculated using a 
nonlinear curve fit. The experiment was independently performed at least twice with similar results.JEM VOL. 208, January 17, 2011 
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Binding by the CDR2 loop involved a combination of 
side chain and main chain contacts (Table I). The Q48A mu-
tant  showed  substantially  reduced  DQ1-MBP85-99  binding 
(108 µM; Fig. 7 b). However, the binding contribution from 
two main chain hydrogen bonds (CDR2 Thr 50–DQ1 His 
68 and CDR2 Ala 53–DQ1 Gln 57) could not be assessed 
with these mutants (Table I), which made it difficult to deter-
mine the total contribution of this TCR loop to DQ1 binding.
In contrast, CDR3 contacts were predominantly made 
by side chains. CDR3 E98A and F95A mutations resulted 
in a severe reduction in binding (>250 µM for both mutants). 
CDR3 F95 formed the majority of peptide contacts, and 
mutation to alanine greatly reduced TCR binding affinity for 
DQ1-MBP85-99. Nevertheless, this mutation did not assess the 
entire contribution by F95 because it did not eliminate the 
hydrogen bond between the main chain of F95 and the peptide 
side chain P5 Lys. The CDR3 E98A mutation resulted in 
the most substantial reduction in DQ1-MBP85-99 binding be-
cause of loss of two hydrogen bonds to DQ1 R61 and 11 other 
contacts, including two contacts to P5 Lys of the peptide.
CDR3 made no contacts to the peptide and only lim-
ited  contact  to  the  DQ1  helix.  CDR3  L95  contacted 
DQ1 E66, and the L95A mutant showed a substantial re-
duction in affinity (110 µM). The interaction of CDR3  
with the DQ1 helix also involved water-mediated hydrogen 
bonds. DQ1 E66 hydrogen bonded with a water molecule, 
which, in turn, hydrogen bonded with CDR3 main chain 
(S93, A94, L95, and E96) and side chain (D97) residues. It is 
possible that this hydrogen bonding network was destabilized 
by the CDR3 L95A mutation.
The mutagenesis data showed that all three TCR loops 
that contacted the DQ1 helices in the crystal structure con-
tributed to DQ1 binding in this functional assay. The data also 
highlighted the critical energetic role of the CDR3 loop in 
binding to the DQ1-MBP85-99 complex, in particular the im-
portant contributions by CDR3 F95 and E98, which made 
many contacts to the peptide (CDR3 F95) and DQ1 (CDR3 
E98) in the structure.
DISCUSSION
Autoaggressive T cells have to meet two competing require-
ments: they have to escape negative selection in the thymus, 
yet they need to be capable of initiating TCR signals of suffi-
cient strength upon recognition of the self-antigen in the tar-
get organ of the disease. The prior structural characterization 
of two human TCRs from MS patients (Hahn et al., 2005; Li 
et al., 2005) and of three mouse TCRs from the EAE model 
(Maynard et al., 2005; Feng et al., 2007) showed in each case 
significant structural alterations that impaired TCR binding 
to the MHC-bound self-peptide (Wucherpfennig et al., 2009). 
The human TCRs bound with an altered topology, whereas 
the mouse TCRs bound with a normal topology. However, 
in all cases the interaction with the peptide was compromised 
either because of a shift in TCR binding (human TCRs) or 
partial  occupancy  of  the  peptide  binding  groove  (murine 
TCRs). The structure of the self-reactive Hy.1B11 TCR 
key TCR contact residues for DQ1 and the MBP85-99 peptide. 
All TCR residues that contacted DQ1 were mutated to ala-
nine, except native alanine or glycine residues. In addition, 
CDR3 F95 was mutated to alanine, given its central role in 
peptide recognition (Fig. 7, a and b). For each mutant, nine 
concentrations were tested under equilibrium binding condi-
tions to obtain reliable affinity measurements (Fig. S5). As a 
control, a double mutant of two noncontacting residues in 
CDR1 and CDR2 (N31A and S52A) was generated. 
This double mutant showed an affinity to DQ1-MBP85-99 
close to wild-type Hy.1B11 TCR (13.8 and 14.3 µM, respec-
tively). Four of the nine mutants had greatly reduced affinities 
for DQ1-MBP85-99, and these targeted TCR residues made 
contacts solely to DQ1 (CDR3 L95A, 110 µM), to both DQ1 
and MBP85-99 peptide (CDR2 Q48A, 108 µM; and CDR3 
E98A, >250 µM), or only the peptide (CDR3 F95A, 
>250 µM). These mutagenesis data also showed that the un-
usual TCR binding mode was not a crystallization artifact.
Figure 7.  TCR mutagenesis identifies key contact residues in the 
CDR2 and CDR3 loops. (a) TCR point mutants are shown as colored 
balls: mutations in CDR2 in shades of green, CDR3 mutants in shades 
of red, and the CDR3 mutant in orange. Darker colors indicate stronger 
effects of mutations. pMHC is shown as a cartoon in silver. (b) Table 
showing the equilibrium binding affinity constants of TCR mutants. The 
number of contacts made to peptide or MHC by each residue are enumer-
ated, along with the number of contacts disrupted by substitutions with 
alanine. Hydrogen bonds are indicated in parentheses. The equilibrium 
binding experiments were performed at least twice.98 Altered self-pMHC engagement by an autoreactive TCR | Sethi et al.
peptides bulging out of the MHC class I binding groove.   
A super-bulged 13-amino peptide bound to HLA-B*3508   
is recognized by SB27 TCR and the interface is dominated   
by TCR–peptide interactions. Nevertheless, each of the four 
germline-encoded TCR loops contacts the MHC protein, 
even though these interactions are limited (Tynan et al., 2005). 
In another example, the ELS4 TCR flattens a peptide bulging 
out of the groove of HLA-B*3501, which enables more ex-
tensive MHC contacts. Again, all four germline-encoded 
loops are involved in MHC binding (Tynan et al., 2007). The 
BM3.3 TCR shows cross-reactivity between  VSV8 and pBMI 
peptides bound to H-2Kb, and there are large differences in 
the contribution of the V and V chains to the interface be-
tween the two structures (Reiser et al., 2000). Nevertheless, 
all four germline-encoded TCR loops contribute to MHC 
recognition in both complexes.
The YAe62 TCR was isolated from mice in which nega-
tive selection was severely limited by expression of a single 
MHC class II–peptide complex in the thymus (Huseby et al., 
2005). Even though  YAe62 TCR contacts both MHC helices, 
it has a substantially larger interaction surface with the 1 
than the 1 helix of the MHC molecule because of a tilt in 
TCR binding (Dai et al., 2008). Unbalanced TCR inter-
actions with the two MHC helices can thus occur in T cells 
that were either not subjected to negative selection (YAe62 
TCR) or escaped elimination in the thymus (Hy.1B11 TCR). 
Furthermore, there are now three TCRs that recognize the 
bound peptide using only one CDR3 loop:  YAe62 and BM3.3 
TCRs with their CDR3 loops and Hy.1B11 with its CDR3 
loop (Reiser et al., 2000; Dai et al., 2008). The YAe62 TCR is 
extremely cross-reactive to both peptide and MHC variants, 
and the BM3.3 TCR was shown to cross react with a viral 
octapeptide presented by H-2Kb. Peptide recognition by a 
single CDR3 loop is therefore also unusual within the large 
structural database that is now available.
The  importance  of  the  germline  loops  of  both TCR 
chains in MHC restriction has been repeatedly demonstrated 
using mutagenesis approaches and analysis of natural MHC 
micropolymorphisms (Sim et al., 1996; Manning et al., 1998; 
Wu et al., 2002; Huseby et al., 2006). Recent structural and 
functional studies strongly support the hypothesis that the 
conventional diagonal TCR binding mode is the result of   
coevolution between MHC and TCR genes (Turner et al., 
2006; Feng et al., 2007; Dai et al., 2008; Marrack et al., 2008; 
Garcia et al., 2009). The diagonal binding orientation on the 
pMHC surface is similar among most crystallized  TCRs, 
but because of variation in the binding angle it has not been 
possible to identify conserved MHC residues contacted by all 
TCRs (Baker and Wiley, 2001; Rudolph et al., 2006). How-
ever,  seven  crystal  structures  involving  six  different V8.2 
TCRs and one  V8.1 TCR that bound mouse I-A molecules 
showed a close convergence of CDR1 and CDR2 con-
tacts with the I-A 1 helix (Garcia et al., 2009). These results 
suggest that particular V domains have preferred binding sites 
on the MHC helices. In mice with a single rearranged TCR- 
chain, mutation of the CDR2 residues Tyr46 or Tyr48 to   
represents the first case in which only one of the four germline-
encoded TCR loops interacts with the MHC helices. Fur-
thermore, only one of the CDR3 loops interacts with the 
peptide, limiting TCR specificity to a short peptide segment (P2 
His, P3 Phe, and P5 Lys). The structure thus explains how 
Hy.1B11 TCR responds to multiple microbial peptides that 
share limited sequence similarity with MBP85-99, in particular 
P3 Phe, a basic residue at P5, and hydrophobic anchors at P1 
and P4 (Fig. S6; Wucherpfennig and Strominger, 1995).
The Hy.1B11 and Ob.1A12 TCRs recognize the MBP85-99 
peptide bound in the same register to DQ1 and DR2, respec-
tively (Fig. S3). The structures of the bound peptides are thus 
quite similar, except that the P4 Phe side chain is posi-
tioned deeper in the hydrophobic P4 pocket of DQ1 (Fig. S3 c). 
Interestingly, specificity of both TCRs is focused on the P2, 
P3, and P5 peptide sidechains, but through different structural 
mechanisms; Ob.1A12 TCR is shifted toward the peptide 
N terminus, which centers the CDR3 loops over P2 His, 
whereas Hy.1B11 is positioned over the center of the peptide 
binding groove but recognizes peptide side chains only through 
CDR3 and not CDR3. It is possible that both TCRs bind 
to this peptide segment because it is more firmly anchored in 
the peptide binding groove, whereas the C-terminal part of 
the MBP85-99 peptide is raised in both structures (Fig. S3 c; 
Smith et al., 1998). In both cases, the TCR contacts one of the 
MHC helices in the typical location, either the MHC class II 
1 chain helix (Hy.1B11 TCR- chain with CDR2 loop) 
or the MHC class II 1 helix (Ob.1A12 TCR- chain with 
CDR1 and CDR2 loops; Fig. S7). However, the germline-
encoded loops of the other TCR chain either do not engage 
the MHC molecule (Hy.1B11) or bind in a highly unusual 
location (Ob.1A12).
In the majority of previously determined structures, all 
four germline-encoded loops contact the MHC helices (21 of 
29 structures, with each TCR counted only once using the 
structure with the principal pMHC ligand; Rudolph et al., 
2006; Marrack et al., 2008; Garcia et al., 2009). These include 
12 of 17 structures involving MHC class I and 9 of 12 struc-
tures involving MHC class II molecules. In seven structures, 
three germline-encoded TCR loops interact with the MHC 
helices (four MHC class I and three MHC class II restricted 
TCRs). These seven include two human self-reactive TCRs 
(Ob.1A12, 3A6) with a shifted binding topology toward to the 
peptide N terminus (Hahn et al., 2005; Li et al., 2005). In each 
of these seven cases, one of the CDR3 loops contacts both 
MHC helices. The A6 TCR that recognizes a HLA-A2–bound 
HTLV-1 Tax peptide uses the CDR1 and CDR2 loops to 
bind to the HLA-A2 2 helix, but the CDR1 and CDR2 
loops do not contact the HLA-A2 1 helix (Garboczi et al., 
1996). However, the CDR3 loop has a large footprint and 
interacts with both MHC 1 and 2 helices. In addition, both 
MHC helices are contacted by the CDR1 loop. This large 
structural database permits the conclusion that the interaction 
of Hy.1B11 TCR with its MHC molecule is unusual.
There are now several examples in which there are un-
usual features of peptide recognition, such as TCR binding to JEM VOL. 208, January 17, 2011 
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MATERIALS AND METHODS
Protein expression and complex formation. Hy.1B11 TCR used the 
gene segments TRAV13-1*02, TRAJ48*01 (non-nucleotide–encoded se-
quence, g; CDR3 protein sequence, AASSFGNEKLT) and TRBV7-3*01, 
TRBD2*01, TRBJ2-3*01 (non-nucleotide–encoded sequence, cctcggccct; 
CD3 protein sequence, ATSALGDTQY). In the expression construct, the 
MBP85-99 peptide was attached to the N terminus of the TCR- chain 
through  a  flexible  octapeptide  linker  (GGSGGGGG),  as  reported  by 
Hennecke et al. (2000). The interchain disulfide bond located at the C termi-
nus of the C and C Ig domains was moved to the N-terminal part of these 
domains (replacement of C Thr48 and C Ser57 with cysteines) to enhance 
refolding of TCR heterodimer (Boulter et al., 2003). The chains were sepa-
rately cloned into pET-22b vector (Novagen), and inclusion bodies produced 
in BL21(DE3) E. coli cells (Novagen) were dissolved in 6 M guanidine hydro-
chloride, 10 mM dithiothreitol, and 10 mM EDTA. To initiate refolding, 
TCR- and - chains were diluted at a 1:1 molar ratio to a concentration of 
25 µg/ml of each chain in a refolding buffer containing 4.5 M urea, 0.55 M 
l-arginine–HCl, 100 mM Tris-HCl, pH 8.2, 1 mM of reduced glutathione 
(GSH), and 0.1 mM of oxidized glutathione (GSSH). After 40 h at 4°C, the 
refolding mixture was dialyzed twice against deionized water and twice against 
10 mM Tris-HCl, pH 8.0. Refolded TCR was purified by anion exchange 
chromatography  using  Poros  PI  (Applied  Biosystems)  and  MonoQ  (GE 
Healthcare) columns. TCR mutants were generated by overlapping PCR and 
cloned into the pET-22b vector (Novagen). These mutant proteins were re-
folded and purified using the same procedure as wild-type TCR Hy.1B11.
DQ1 was produced in glycosylation-deficient Lec3.2.8.1 cells (Stanley, 
1989). The CLIP peptide was attached to the N terminus of the DQ1 chain 
using a linker with a thrombin cleavage site, and the two chains were cloned 
into a vector that drives expression of glutamine synthetase to enable selec-
tion of transfected clones in glutamine-deficient media (Day et al., 2003). 
Stable clones were produced under methionine sulphoximine selection and 
tested for DQ1 secretion by Western blotting. The clone with the highest 
DQ1 production level was expanded in a hollow fiber bioreactor (AccuSyst 
miniMax;  Biovest  International)  and  secreted  DQ1  was  affinity-purified   
using mAb 9.3.F10 (American Type Culture Collection). Fos and Jun leucine 
zipper dimerization domains at the C termini used to facilitate DQ1 hetero-
dimer formation were removed by V8 protease cleavage.
After cleavage of the CLIP peptide linker, complexes were formed by 
permitting binding of the TCR- chain–linked MBP85-99 peptide to the 
DQ1 binding site. TCR, DQ1, and HLA-DM were incubated at a molar   
ratio of 6:4:1 for 18 h at 25°C at a pH of 5.4, and the complex was separated 
from components by gel filtration (Superdex S-200 column; GE Healthcare) 
and anion-exchange chromatography (MonoQ; GE Healthcare).
Crystallization and data collection. The complex was determined to be 
pure by SDS-PAGE and isoelectric focusing PAGE. The complex was con-
centrated to 7.5 mg/ml in 10 mM Hepes, pH 7.2. A crystallization matrix 
based on conditions in which other TCR–MHC complex crystals were ob-
tained was used as a starting point for screening. Crystals were obtained in 
multiple conditions. The final crystals for data collection were grown by the 
hanging-drop vapor-diffusion method against a reservoir of 0.1 M ammonium 
sulfate, 8–10% PEG 8000, and 50 mM sodium citrate, pH 6.1, at 24°C. Crys-
tals were cryoprotected by the addition of ethylene glycol to 25%. Data were 
collected at 100 K at the National Synchrotron Light Source at Brookhaven 
National Laboratories (Upton, New York) using beamline X29 at a wave-
length of 1.0 Å by participating in the mail-in program. The data were pro-
cessed with the HKL2000 program (Otwinowski and Minor, 1997).
Structure determination and refinement. The structure of the complex 
was determined by molecular replacement using PHASER software (McCoy 
et al., 2007). A BLAST (Altschul et al., 1990) search of the sequences of TCR 
Hy.1B11 and DQ1 against the PDB database was used to find the best model 
for  molecular  replacement.  Separate  BLAST  searches  for TCR-  and   
- chains were performed and the TCR with the highest consensus score (PDB 
accession code 3HG1) was used for molecular replacement. DQ6 (PDB   
alanine caused a substantial reduction in the number of thy-
mocytes. Furthermore, these mutations changed V usage, 
which is apparently a compensatory mechanism to enable 
positive selection of some T cells despite reduced MHC bind-
ing by the V chain (Scott-Browne et al., 2009). Studies on 
MHC class I restricted TCRs have also identified MHC   
residues that are frequently recognized by TCRs, but the   
contribution of these MHC residues to binding differs among 
individual TCRs (Burrows et al., 2010).
CDR2 residues of Hy.1B11 were found to interact with 
a similar set of MHC positions as other MHC class II re-
stricted TCRs. Given that CDR2 is the only germline- 
encoded TCR loop that contacts DQ1, it is possible that the 
placement of this loop on the DQ1 1 helix contributed 
to the diagonal position of this TCR over the center of the 
DQ1-MBP85-99 surface. Alanine scanning mutagenesis showed 
that the two CDR3 loops contributed significantly to DQ1 
binding. CDR3 loops have been shown to be flexible (Garcia 
et al., 1998; Hare et al., 1999; Armstrong et al., 2008) and, in 
addition to contacting the peptide, they can make important 
contributions to MHC binding (Garboczi et al., 1996; Borg 
et  al.,  2005). The  orientation  of  Hy.1B11 TCR  on  the   
DQ1-MBP85-99 surface therefore appears to result from the 
combined binding contributions of the CDR2 and both 
CDR3 loops.
The  unusual  structure  of  the  Hy.1B11 TCR–DQ1-
MBP85-99 complex also raises the important question of how 
the corresponding human T cell escaped from negative selec-
tion in the thymus, but caution has to be used to extrapolate 
from structural data to complex in vivo events. This TCR has 
a higher affinity for its pMHC target than the previously   
crystallized self-reactive TCRs Ob.1A12 and 3A6 (Hahn   
et al., 2005; Li et al., 2005). However, the Hy.1B11 TCR is 
HLA-DQ restricted, whereas the other two TCRs are HLA-DR   
restricted.  HLA-DQ  molecules  are  expressed  at  10-fold 
lower levels than HLA-DR molecules (Roucard et al., 1996), 
and the higher affinity of Hy.1B11 TCR may therefore be re-
quired for this TCR to adequately respond to the self-peptide 
on peripheral antigen-presenting cells. HLA-DQ molecules 
are expressed at very low levels in the medulla of the thymus 
(Ishikura et al., 1987), which may have facilitated escape of 
negative selection by the Hy.1B11 T cell. It is also possible 
that the tilted binding mode of Hy.1B11 TCR binding affects 
formation of higher order structures among TCRs and/or 
other proteins involved in T cell activation at the immuno-
logical synapse.
In summary, this self-reactive TCR interacts in an un-
usual manner with both the self-peptide and the MHC 
molecule. The binding mode differs substantially from the 
other two autoimmune TCRs that have been crystallized, 
demonstrating  that  there  are  multiple  unusual  ways  for 
self-reactive TCRs to bind their pMHC ligand. Particu-
larly intriguing is the limited interaction surface with the 
self-peptide and the functional relevance of this finding 
for the activation of this self-reactive T cell clone by micro-
bial peptides.100 Altered self-pMHC engagement by an autoreactive TCR | Sethi et al.
Institute (to D.A. Schubert). Data were collected at beamline X29 of the National 
Synchrotron Light Source. Financial support for the National Synchrotron Light 
Source comes principally from the Offices of Biological and Environmental Research 
and of Basic Energy Sciences of the US Department of Energy, and from the 
National Center for Research Resources of the National Institutes of Health.
The authors declare no competing financial interests.
Submitted: 14 April 2010
Accepted: 19 November 2010
REFERENCES
Altschul, S.F., W. Gish, W. Miller, E.W. Myers, and D.J. Lipman. 1990. 
Basic local alignment search tool. J. Mol. Biol. 215:403–410.
Armstrong, K.M., K.H. Piepenbrink, and B.M. Baker. 2008. Conformational 
changes and flexibility in T-cell receptor recognition of peptide-MHC 
complexes. Biochem. J. 415:183–196. doi:10.1042/BJ20080850
Baker, B.M., and D.C. Wiley. 2001. alpha beta T cell receptor ligand- 
specific  oligomerization  revisited.  Immunity.  14:681–692.  doi:10.1016/ 
S1074-7613(01)00160-1
Borg,  N.A.,  L.K.  Ely,  T.  Beddoe,  W.A.  Macdonald,  H.H.  Reid,  C.S. 
Clements,  A.W.  Purcell,  L.  Kjer-Nielsen,  J.J.  Miles,  S.R.  Burrows,   
et al. 2005. The CDR3 regions of an immunodominant T cell recep-
tor dictate the ‘energetic landscape’ of peptide-MHC recognition. Nat. 
Immunol. 6:171–180. doi:10.1038/ni1155
Boulter, J.M., M. Glick, P.T. Todorov, E. Baston, M. Sami, P. Rizkallah, 
and  B.K.  Jakobsen.  2003.  Stable,  soluble  T-cell  receptor  molecules 
for  crystallization  and  therapeutics.  Protein  Eng.  16:707–711.  doi:10 
.1093/protein/gzg087
Brunger, A.T. 2007. Version 1.2 of the Crystallography and NMR system. 
Nat. Protoc. 2:2728–2733. doi:10.1038/nprot.2007.406
Burrows,  S.R.,  Z.  Chen,  J.K.  Archbold,  F.E.  Tynan,  T.  Beddoe,  L. 
Kjer-Nielsen, J.J. Miles, R. Khanna, D.J. Moss, Y.C. Liu, et al. 2010. 
Hard wiring of T cell receptor specificity for the major histocompatibil-
ity complex is underpinned by TCR adaptability. Proc. Natl. Acad. Sci. 
USA. 107:10608–10613. doi:10.1073/pnas.1004926107
Cole, D.K., N.J. Pumphrey, J.M. Boulter, M. Sami, J.I. Bell, E. Gostick, 
D.A. Price, G.F. Gao, A.K. Sewell, and B.K. Jakobsen. 2007. Human 
TCR-binding affinity is governed by MHC class restriction. J. Immunol. 
178:5727–5734.
Collaborative Computational Project, Number 4. 1994. The CCP4 suite: 
programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 
50:760–763. doi:10.1107/S0907444994003112
Costantini,  S.,  A.  Paladino,  and  A.M.  Facchiano.  2008.  CALCOM:  a 
software for calculating the center of mass of proteins. Bioinformation. 
2:271–272.
Dai, S., E.S. Huseby, K. Rubtsova, J. Scott-Browne, F. Crawford, W.A. 
Macdonald,  P.  Marrack,  and  J.W.  Kappler.  2008.  Crossreactive   
T Cells spotlight the germline rules for alphabeta T cell-receptor inter-
actions with MHC molecules. Immunity. 28:324–334. doi:10.1016/ 
j.immuni.2008.01.008
Day, C.L., N.P. Seth, M. Lucas, H. Appel, L. Gauthier, G.M. Lauer, G.K. 
Robbins,  Z.M.  Szczepiorkowski,  D.R.  Casson,  R.T.  Chung,  et  al. 
2003. Ex vivo analysis of human memory CD4 T cells specific for hepa-
titis C virus using MHC class II tetramers. J. Clin. Invest. 112:831–842.
Ellmerich, S., M. Mycko, K. Takacs, H. Waldner, F.N. Wahid, R.J. Boyton, 
R.H. King, P.A. Smith, S. Amor, A.H. Herlihy, et al. 2005. High in-
cidence of spontaneous disease in an HLA-DR15 and TCR transgenic 
multiple sclerosis model. J. Immunol. 174:1938–1946.
Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecu-
lar graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126–2132. doi:10 
.1107/S0907444904019158
Fairchild, P.J., R. Wildgoose, E. Atherton, S. Webb, and D.C. Wraith. 
1993. An autoantigenic T cell epitope forms unstable complexes with 
class II MHC: a novel route for escape from tolerance induction. Int. 
Immunol. 5:1151–1158. doi:10.1093/intimm/5.9.1151
Feng,  D.,  C.J.  Bond,  L.K.  Ely,  J.  Maynard,  and  K.C.  Garcia.  2007. 
Structural evidence for a germline-encoded T cell receptor-major histo-
compatibility complex interaction ‘codon’. Nat. Immunol. 8:975–983. 
doi:10.1038/ni1502
accession code 1UVQ) was used as the model for DQ1 (Siebold et al., 2004). 
PHASER gave a clear and unambiguous solution which could be repro-
duced using the MOLREP program (Vagin and Teplyakov, 1997). Refine-
ment and rebuilding were performed using crystallography and nuclear 
magnetic resonance system (CNS) and COOT (Emsley and Cowtan, 2004; 
Brunger, 2007). The overall density was good with the exception of density 
for residues DQ1 46–51, which usually form a short ascending loop in most 
HLA molecules that has been reported to be important for DM engagement. 
Stereochemical parameters of the structure were evaluated with the PRO-
CHECK program (Laskowski et al., 1993) and found to be within reasonable 
limits with 91% of the residues in the most favored region and none in   
the disallowed regions. Buried surface area calculations were done using 
AREAIMOL (Lee and Richards, 1971) using a probe radius of 1.4 Å. 
CALCOM (Costantini et al., 2008) was used for all center of mass calculations 
and all figures were made with PYMOL. Atomic contacts were determined 
using CONTACT as implemented in CCP4i (CCP4 suite; Collaborative 
Computational Project, Number 4, 1994); atoms within a 4 Å distance of each 
other were considered to be in contact. The TCR crossing angle was calcu-
lated by drawing a vector between the center of mass of the V and V domains 
and measuring the angle as it intersects a line drawn between the P1 and P9 
peptide anchor residues. Relative tilt was calculated as in Teng et al. (1998).
Affinity measurements. The interaction of Hy.1B11 TCR with the DQ1–
MBP85-99 complex was assessed by surface plasmon resonance using a Biacore 
3000 instrument (GE Healthcare). DQ1 with a biotinylated C-terminal BirA 
tag was captured on a Biacore streptavidin chip. After immobilization of 
700, 1,000, or 3,000 resonance units for analysis of TCR binding, solutions 
containing different concentrations of soluble monomeric wild-type or   
mutant TCR Hy.1B11 in 10 mM Hepes, 150 mM NaCl, and 0.005% Tween   
20 were injected at 15 µl/min at 25ºC. Flow cells with DQ1-CLIP or DR2/
MBP85-99 complexes were used as specificity controls. BIAevaluation version 
4.1 was used for all data analysis. Equilibrium Kd values were obtained by 
nonlinear curve fitting of subtracted curves using the steady-state affinity fit-
ting mode in BIAevaluation version 4.1. Kd values are reported as mean and 
standard deviation.
Analysis  of  peptide  analogues. Proliferation assays with the Hy.1B11   
T  cell  clone  were  performed  using  EBV  transformed  B  cell  line  9009 
(DQAI*0102, DQBI*0502) as antigen-presenting cells. B cells were irradi-
ated (5,000 rads) and treated with 50 µg/ml mitomycin C (EMD) for 30 min 
at 37°C. Assays were set up in 96-well U bottom plates with 5 × 104 T cells 
and 104 B cells in 0.2 ml of serum-free AIM-V media supplemented with   
2 mM GlutaMAX. Peptides were tested in triplicates at concentrations of 0.1 
and 1 µM. After 72 h of co-culture, T cell proliferation was determined by 
[3H]-thymidine incorporation.
PDB  accession  no. The  coordinates  of  the  Hy.1B11-DQ1–MBP85-99  
complex have been deposited under PDB accession no. 3PL6.
Online supplemental material. Fig. S1 shows electron density for critical 
parts of the crystal structure. Fig. S2 shows the center of mass of V and V 
domains of TCR Hy.1B11. Fig. S3 shows that the MBP85-99 peptide binds in 
the same register to DQ1 and DR2. Fig. S4 shows a specificity control for 
surface plasmon resonance experiments, and Fig. S5 shows equilibrium bind-
ing data for the TCR mutants. Fig. S6 shows alignment of microbial peptides 
that stimulate the Hy.1B11 T cell clone. Fig. S7 shows comparison of the 
placement of TCR- germline-encoded loops by the human autoimmune 
Ob.1A12 TCR and other MHC class II restricted TCRs. Table S1 shows data 
collection and refinement parameters. Table S2 shows the sequence of CDR3. 
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20100725/DC1.
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